{"ATC Code":"QI01AN01","Abbreviation":"","Aliases":["Isonicotinic acid hydrazide","Isonicotinohydrazide","Isoniazide","Rimifon","Nydrazid","Cotinazin","Hydrazid","Iscotin","Mybasan","Isonicotinylhydrazine"],"Biological Half-Life":"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.","CAS":"54-85-3","ChEBI":"CHEBI:6030","ChEMBL":"CHEMBL64","ChemicalClasses":[],"Chirality":"achiral","Color/Form":"COLORLESS OR WHITE CRYSTALS, OR A WHITE, CRYSTALLINE POWDER","Decomposition":"When heated to decomposition it emits toxic fumes of /nitrogen oxides/.","Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antitubercular Agents","Drug Indication":"Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.","Drug Warnings":"The incidence of and risk factors associated with hepatotoxicity in patients with chronic hepatitis have not been systematically studied. Therefore, we conducted a prospective study that included former drug users who were treated with isoniazid for latent tuberculosis infection. Of 415 patients, 20 (4.8%; 95% confidence interval [CI], 3-7.4) had hepatotoxicity diagnosed, and 6 (1.4%; 95% CI, 0.5-3.2) developed clinical hepatitis, none of whom had serious symptoms. The only 2 factors independently associated with isoniazid hepatotoxicity were excessive alcohol consumption (odds ratio [OR]; 4.2, 95% CI, 1.6-10.8; P=.002) and a high baseline alanine transaminase level (OR, 4.3; 95% CI, 1.6-11.4; P=.002). The presence of hepatitis C virus antibodies was associated with hepatotoxicity only on univariate analysis. Treatment with isoniazid in drug users appears to be safe and well tolerated, although frequent asymptomatic elevations in transaminase levels were observed.","DrugClasses":[],"EINECS":"200-214-6","EliminationHalfLife":"0.5–1.6h (fast acetylators), 2-5h (slow acetylators)","Esters":["propionate"],"European Community (EC) Number":"200-214-6","FDA Pharmacological Classification":"V83O1VOZ8L","Flash Point":"374 °F (NTP, 1992)","HMDB ID":"HMDB0015086","HeavyAtomCount":10,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antitubercular Agents","IUPACName":"pyridine-4-carbohydrazide","Impurities":["isoniacinamide","isonicotinic acid","picolinohydrazide","4-cyanopyridine","hydrazine","nicotinic acid hydrazide"],"InChI":"InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)","InChIKey":"QRXWMOHMRWLFEY-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Compounds that interfere with FATTY ACID SYNTHASE resulting in a reduction of FATTY ACIDS. This is a target mechanism in humans of some ANTINEOPLASTIC AGENTS and ANTI-OBESITY AGENTS and of some ANTI-INFECTIVE AGENTS which interfere with CELL WALL and CELL MEMBRANE formation. (See all compounds classified as Fatty Acid Synthesis Inhibitors.)","Melting Point":"340.5 °","MolecularFormula":"C\u003csub\u003e6\u003c/sub\u003eH\u003csub\u003e7\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO","MolecularWeight":"137.14 g/mol","Pharmacodynamics":"Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically \u003ci\u003eM. tuberculosis\u003c/i\u003e, \u003ci\u003eM. bovis\u003c/i\u003e and \u003ci\u003eM. kansasii\u003c/i\u003e. It is a highly specific agent, ineffective against other microorganisms. Isoniazid is bactericidal when mycobacteria grow rapidly and bacteriostatic when they grow slowly.","Physical Description":"Isoniazid appears as odorless colorless or white crystals or white crystalline powder. Taste is slightly sweet at first and then bitter. pH (1% aqueous solution) 5.5-6.5. pH (5% aqueous solution) 6-8. (NTP, 1992)","PrevSalts":[],"PubChemId":3767,"Record Description":["Isoniazid appears as odorless colorless or white crystals or white crystalline powder. Taste is slightly sweet at first and then bitter. pH (1% aqueous solution) 5.5-6.5. pH (5% aqueous solution) 6-8. (NTP, 1992)","Isoniazide is a carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine. It has a role as an antitubercular agent and a drug allergen. It is functionally related to an isonicotinic acid.","Isoniazid is an antibacterial prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the prevention and treatment of tuberculosis (TB).","TB can be an opportunistic infection (OI) of HIV.","Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.","Isoniazid is an Antimycobacterial.","Isoniazid is the most reliable and most commonly used medication for tuberculosis. Isoniazid therapy is often associated with minor, transient and asymptomatic elevations in serum aminotransferase levels but, more importantly, isoniazid is a well known cause of acute clinically apparent liver injury which can be severe and is sometimes fatal.","Isoniazid has been reported in Aspergillus ochraceopetaliformis, Ganoderma colossus, and other organisms with data available.","Isoniazid is a synthetic derivative of nicotinic acid with anti-mycobacterial properties.  Although its mechanism of action is still unclear, isoniazid appears to block the synthesis of mycolic acids, major components of the mycobacterial cell wall. This agent is only active against actively growing mycobacteria because, as a pro-drug, it requires activation in susceptible mycobacterial species. Isoniazid also interferes with mycobacterial metabolism of vitamin B6.  Resistance occurs due to decreased bacterial wall penetration. (NCI04)","ISONIAZID is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 4 approved and 8 investigational indications. This drug has a black box warning from the FDA.","Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. ","Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.","See also: Isoniazid; rifampin (component of); Stevia rebaudiuna Leaf (part of); Isoniazid; pyrazinamide; rifampin (component of).","Isoniazide is a carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine. It has a role as an antitubercular agent and a drug allergen. It is functionally related to an isonicotinic acid.","LiverTox|Antimicrobial|Antituberculosis|Hydrazine"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Isoniazid","Name":"Isoniazid","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q423169","Name":"Isoniazid","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00951","Name":"Isoniazid","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3767","Name":"Isoniazid","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL64","Name":"Isoniazid","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6030","Name":"Isoniazid","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=54-85-3","Name":"Isoniazid","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015086","Name":"Isoniazid","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07054","Name":"Isoniazid","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/V83O1VOZ8L","Name":"Isoniazid","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020755","Name":"Isoniazid","Sub":false}]}],"SMILES":"C1=CN=CC=C1C(=O)NN","Scheduling":[{"gov":"Canada","schedule":"prescription only substance"},{"gov":"United States","schedule":"prescription only substance"}],"Solubility":"13.7 [ug/mL] (The mean of the results at pH 7.4)","Stability/Shelf Life":"STABLE AT ROOM TEMP FOR MORE THAN 14 DAYS IN AQ SOLN AND MORE THAN 6 WK WHEN STORED AT ABOUT 4 °C.","StoreUNII":["V83O1VOZ8L"],"StructureBase64":"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","Therapeutic Uses":"Antitubercular Agents","Title":"Isoniazid","UNII":"V83O1VOZ8L","Wikidata":"Q423169","Wikipedia":"Isoniazid","XLogP":-0.7,"pH":"pH of a 1% aqueous solution 5.5 to 6.5"}